Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Onconetix, Inc.

  • CINCINNATI, Ohio
  • Public · NASDAQ: ONCO
  • 2 employees
$1.2MMarket cap
$815.4KRevenue · FY2025
-$14.0MNet income
2Employees
ONCONASDAQ
2022IPO

About Onconetix, Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$815.4K
Net income
-$14.0M
Total assets
$24.9M
Market cap
$1.2M

Source: SEC EDGAR · updated Jun 8, 2026

NASDAQ: ONCO

15-minute delayed · data by Polygon.io

Market cap
$1.2M
Open
Day range
Prev close
Volume
IPO date
Feb 18, 2022

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Onconetix, Inc..

Write a review
Explore

Similar companies

Browse all →